To better understand employer priorities, we ran a poll on LinkedIn in April 2026 and asked, “What’s creating the most pressure in your pharmacy benefits strategy right now?”
The results:
- High‑cost medication — 46%
- GLP‑1 and weight‑loss drugs — 43%
- Visibility into pharmacy costs — 5%
- Balancing cost control — 7%
High‑cost drugs are reshaping employer health spending and workforce health. Employers need sustainable strategies that maintain access and quality while managing spend volatility. This guide presents data‑driven approaches, benefit designs, and partnership models that support employees and stabilize budgets — practical strategies for managing high‑cost medications across various plan designs.
High-cost drugs
Specialty, biologic, and one‑time gene and cell therapies now drive a growing share of total medical and pharmacy costs. A small group of members often accounts for a disproportionate share of spend due to complex, high‑cost conditions. For self‑funded employers, these claims can arise suddenly and unpredictably, making specialty drug cost management a core planning priority.
The clinical and workforce impacts are significant. When employees access and adhere to appropriate therapies, complications decline, absenteeism falls, and productivity improves. Conversely, barriers to access or poor adherence can lead to increased hospitalizations, emergency visits, and presenteeism. With an expanding pipeline, rising list prices, shifting sites of care, and new uses for existing drugs, pressure on pharmacy budgets may continue.
Data‑driven approaches to high‑cost cases
- Build a unified total cost‑of‑care view by integrating medical and pharmacy claims. Segment by condition, drug class, site of care, prescriber, and administration frequency to find the highest‑impact opportunities.
- Use risk stratification and predictive models that combine diagnoses, utilization, adherence, social risk factors, and prescriber patterns to flag members before costs escalate. Trigger targeted interventions — such as pharmacist outreach, case management, or site‑of‑care optimization — at the right moment.
- Evaluate interventions with a balanced scorecard that includes total cost of care (medical and pharmacy), condition‑specific outcomes, medication adherence, and member experience. Whenever possible, consider using baselines or control groups to measure avoided events (admissions, ED visits) and support ROI claims.
Benefit design and cost‑management
Align benefits with clinical value while maintaining strong member protections. Tailor solutions to fit plan size, risk tolerance, and organizational culture.
- Alternative designs: Consider targeted carve‑outs for specialty pharmacy services to improve oversight and service levels. Coordinate manufacturer copay assistance to reduce members’ out‑of‑pocket costs without inflating plan spend. Implement evidence‑based step therapy with rapid clinical exceptions to avoid care delays.
- Clinical management: Make prior authorization clinically rigorous, timely, and transparent. Standardize specialty pathways for dosing, monitoring, and site‑of‑care selection. Support adherence with pharmacist counseling, refill synchronization, proactive follow‑up, and digital reminders to reduce abandonment.
- Financial strategies: Use stop‑loss or reinsurance for catastrophic claims and explore outcomes‑based contracts that tie payment to real‑world performance. Encourage biosimilar adoption when clinically appropriate and expand site‑of‑care optimization to help reduce per‑episode costs without compromising quality.
Expectations from pharmacy management specialists
- Transparency and auditability: Contracts should clearly define rebates, dispensing fees, spreads, and guarantees, and include audit rights. Reporting should provide insights into utilization, unit costs, denial rates, prior authorization turnaround times, and outcome metrics.
- Integrated care coordination: Look for dedicated pharmacist engagement, embedded case management for complex therapies, and structured collaboration with treating providers. Effective partners coordinate transitions to lower‑cost sites of care, monitor lab results and safety, and help members access financial assistance without compromising plan integrity.
- Customization: Best‑in‑class partners benchmark your data, create custom pathways for key conditions, and align interventions with organizational goals (e.g., shifting care from hospital outpatient to ambulatory infusion, accelerating biosimilar conversion). Evaluate clinical governance, data integration, and demonstrated outcomes for similar employer populations.
Governance and measurement strategies
- Start with stakeholder alignment: Engage HR, finance, benefits, legal, and employee representatives to define objectives, acceptable levels of risk, and member protections. Communicate clearly about changes, the rationale behind them, and the support available.
- Pilot and scale: Use phased rollouts. Pilot high‑impact initiatives (e.g., biosimilar policy, site‑of‑care pathway, enhanced prior authorization) with a specific group before broad deployment.
- Establish governance and KPIs: Track total cost of care per condition and per member, medication adherence and persistence, time to therapy initiation and prior authorization turnaround, site‑of‑care shifts, biosimilar conversion rates, and member satisfaction. Hold quarterly reviews, assign ownership, and tie vendor performance to contractual guarantees and service level agreements (SLAs).
Levers and metrics
- Utilization management: Implement evidence‑based step therapy and optimized prior authorization. Measure approval turnaround times, exception rates, and abandonment rates.
- Site of care: Shift care from hospital outpatient settings to ambulatory or home infusion. Measure per‑episode costs, safety events, and member satisfaction.
- Biosimilar adoption: Focus on prescriber engagement and formulary alignment. Measure conversion rates and net costs per dose.
- Financial protection: Use stop‑loss strategies, outcomes‑based contracts, and copay coordination. Measure the frequency of large claims, contract performance, and member out‑of‑pocket exposure.
Real-world examples
Employers that adopted biosimilar conversion policies and expanded ambulatory or home infusion options reduced per‑treatment costs while maintaining clinical outcomes. Others reduced spend by effectively coordinating manufacturer assistance and streamlining prior authorization processes to help prevent therapy abandonment. Start with a rapid opportunity assessment, select two or three initiatives with the highest potential ROI, and mobilize a cross‑functional team to execute, measure, and refine.
Key takeaways for employers
- Integrate medical and pharmacy data to target the highest‑impact conditions and therapies.
- Balance access and affordability with evidence‑based benefit design and robust clinical management.
- Use financial tools and contracting models to help protect against volatility.
- Choose transparent, outcomes‑focused partners with strong clinical and data capabilities.
- Embed governance, measurement, and member protections to enhance the employee experience while managing specialty drug costs.
While visibility and balancing cost control were lower priorities in that snapshot, improving transparency and intentional cost‑control measures remain essential components of any comprehensive strategy. With thoughtful planning and the right partners, employers can manage high‑cost drugs in a way that safeguards member outcomes and provides more predictable, sustainable savings.
